Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Tolebrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Update on the US Regulatory Review of Tolebrutinib in MS
    Update on the US Regulatory Review of Tolebrutinib in MS

    22 Sep 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-22-05-00-00-3153624

    PRESS RELEASE
    22 Sep 2025
    Share Share
    Sanofi's Oral Ms Drug FDA Action Date Shifted To December
    Sanofi's Oral Ms Drug FDA Action Date Shifted To December

    22 Sep 2025

    // BIOSPACE

    https://www.biospace.com/fda/fda-action-date-for-sanofis-oral-multiple-sclerosis-drug-bumped-to-december

    BIOSPACE
    22 Sep 2025
    Share Share
    Tolebrutinib phase 3 data in NEJM show benefit in MS disability
    Tolebrutinib phase 3 data in NEJM show benefit in MS disability

    08 Apr 2025

    // PRESS RELEASE

    https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-04-08-17-11-11-3057931-en.pdf

    PRESS RELEASE
    08 Apr 2025
    Share Share
    Tolebrutinib Submission Accepted In US For Multiple Sclerosis
    Tolebrutinib Submission Accepted In US For Multiple Sclerosis

    25 Mar 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-03-25-06-00-00-3048411

    PRESS RELEASE
    25 Mar 2025
    Share Share
    Tolebrutinib Designated Breakthrough Therapy for Progressive MS
    Tolebrutinib Designated Breakthrough Therapy for Progressive MS

    12 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/13/2996609/0/en/Press-Release-Tolebrutinib-designated-Breakthrough-Therapy-by-the-FDA-for-non-relapsing-secondary-progressive-multiple-sclerosis.html

    GLOBENEWSWIRE
    12 Dec 2024
    Share Share
    AB Science Updates On Masitinib In Multiple Sclerosis
    AB Science Updates On Masitinib In Multiple Sclerosis

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/23/2951617/0/en/AB-Science-provides-an-update-on-the-development-of-masitinib-in-progressive-forms-of-multiple-sclerosis-post-ECTRIMS-2024.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share